June 5, 2019
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
• Top-line data is anticipated in the first half of 2020
• If PSOARING trials are successful, a New Drug Application (NDA) filing with the U.S. Food and Drug...
Dermavant’s
Robust Pipeline
Dermavant’s medical dermatology pipeline includes product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.
Patient-Focused
Innovation
Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a differentiated therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of psoriasis and atopic dermatitis.
June 5, 2019
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
Dermavant’s
Robust Pipeline
Dermavant’s medical dermatology pipeline includes product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.
Patient-Focused
Innovation
Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a differentiated therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of psoriasis and atopic dermatitis.
